First European Advanced Therapies Biotech Investor Day
Euronext hosted and co-organised together with the Alliance for Advanced Therapies the first European Advanced Therapies Biotech Investor Day on 29 November 2013. Leaders of European advanced therapies companies met with investors, brokers, analysts and journalists to showcase the potential of new cell-, tissue-, and gene-based therapies and discuss investment strategies. Eduardo Bravo, Chair of the Alliance for Advanced Therapies, opened the European stock markets in Brussels with a bell ceremony commemorating the first meeting of its kind in Europe.
“Three European companies from the advanced therapies sector have gone public since the beginning of 2013, two of which on Euronext markets: Erytech Pharma (France) and Cardio3 BioSciences (Belgium). We anticipate that many more will follow in the coming years,” declared Vincent Van Dessel, Chairman and Chief Executive Officer of Euronext Brussels.
Belgian Investor Day in Zurich
Euronext hosted the first Belgian Investor Day in Zurich on 4 December 2013 in partnership with Bank Degroof. More than 80 one-to-one meetings were organised between Swiss professional investors and the 14 Belgian listed companies during this day of networking and conferences. Damien Petit, Bank Degroof Senior Economist, provided some perspective on the topic: “The Euro area, light at the end of the tunnel?”
Viohalco: the largest EnterNext listing in 2013
Viohalco, the holding company for a large metals group, celebrated its listing in Brussels on 22 November 2013. The reference price of Viohalco shares was €4.19 per share, valuing the company at €920 million at the listing date. “We are delighted with Viohalco's listing on Euronext Brussels and congratulate the company upon joining a community of over 160 other international issuers listed on our European markets.” said Alain Baetens, Head of Listings of Euronext.
Alain Baetens (Head of Listings Belgium, NYSE Euronext),
ExpertLine: +32/2 509-9595
For more information or for specific questions, please contact Alain Baetens or send an email to %4dyQfirstname.lastname@example.org " rel="nofollow"> MyQuestion@euronext.com .